Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Dec 7;2:244. doi: 10.3389/fmicb.2011.00244

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 Nayak, Sarkar, Perrin, Moghimi, Hoffman, Zhou, Byrne and Herzog.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

PMC Copyright notice

Phenotypic analysis of Treg induced by the rapa/specific peptide tolerization protocol using different routes and schedules of drug administration. DO11.10-tg Rag^−/− BALB/c mice (n = 5 per group) were treated for 4 weeks with rapamycin/ova-specific peptide, after which splenocytes were analyzed by antibody stains and flow cytometry. (A–C) Examples for gating scheme and flow cytometric analysis of FoxP3 (A), GITR (B), and CTLA-4 (C) expression by induced CD4⁺CD25⁺ Treg. (D) Percentage of CD4⁺ T cells of total gated splenocytes, and (E) Percentage of CD25⁺FoxP3⁺ cells of CD4⁺ T cells as a function of treatment. Statistically significant differences between each group and untreated (naïve) control mice are indicated as **P < 0.01, and ****P < 0.0001. (F) Representative examples of CD25 and FoxP3 staining (gated on CD4⁺ splenocytes) for “natural” Treg (isolated from immune competent DO11.10-tg Rag^+/+ mice), and induced Treg from DO11.10-tg Rag^−/− mice treated with the IP or the oral protocol. (G) Percent GITR⁺ cells, and (H) percent CTLA-4⁺ cells amongst CD4⁺CD25⁺FoxP3⁺ Treg. All bar graphs are average ±SD.

Phenotypic analysis of Treg induced by the rapa/specific peptide tolerization protocol using different routes and schedules of drug administration. DO11.10-tg Rag^−/− BALB/c mice (n = 5 per group) were treated for 4 weeks with rapamycin/ova-specific peptide, after which splenocytes were analyzed by antibody stains and flow cytometry. (A–C) Examples for gating scheme and flow cytometric analysis of FoxP3 (A), GITR (B), and CTLA-4 (C) expression by induced CD4⁺CD25⁺ Treg. (D) Percentage of CD4⁺ T cells of total gated splenocytes, and (E) Percentage of CD25⁺FoxP3⁺ cells of CD4⁺ T cells as a function of treatment. Statistically significant differences between each group and untreated (naïve) control mice are indicated as **P < 0.01, and ****P < 0.0001. (F) Representative examples of CD25 and FoxP3 staining (gated on CD4⁺ splenocytes) for “natural” Treg (isolated from immune competent DO11.10-tg Rag^+/+ mice), and induced Treg from DO11.10-tg Rag^−/− mice treated with the IP or the oral protocol. (G) Percent GITR⁺ cells, and (H) percent CTLA-4⁺ cells amongst CD4⁺CD25⁺FoxP3⁺ Treg. All bar graphs are average ±SD.